Asthma | Treatment Algorithms: Claims Data Analysis | Adult Asthma | US | 2023
Two types of pharmacotherapy are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies (e.g., a SABA such as Teva’s ProAir HFA) that treat the acute symptoms of asthma via bronchodilation. Maintenance therapies are inhaled, oral, or biological drugs (e.g., a LABA/ICS such as GSK’s Advair or an anti-IL-5 agent such as AstraZeneca’s Fasenra) that are used to prevent exacerbations by targeting the underlying pathophysiology. Many adult patients receive several agents to treat their asthma. Although multiple well-established therapies are available for adult asthma, the market has seen the approval and launch of even more agents, including novel biologics (e.g., Regeneron / Sanofi’s Dupixent) and generic versions of the blockbuster inhaled drugs (e.g., albuterol sulfate and formoterol / budesonide). These launches have added treatment options and fueled more intense competition in this market.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult asthma patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult asthma patients?
- How have newer biologics, such as Fasenra or Dupixent, been integrated into the treatment algorithm, and what is their source of business?
- What percentage of adult asthma patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of adult asthma patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Content highlights
Markets covered: United States
Key companies: GlaxoSmithKline, AstraZeneca, Teva, Genentech, Merck, Boehringer-Ingelheim, Sanofi, Regeneron, Mylan, Cipla, Par, Perrigo, Prasco
Key drugs: Advair, Symbicort, Dulera, AirDuo, Breo, Dupixent, Fasenra, Nucala, Ventolin, ProAir, montelukast sodium, Flovent, Qvar, Spiriva, Trelegy.
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
